Compass Therapeutics Stock Today
| CMPX Stock | USD 1.38 0.01 0.73% |
Performance3 of 100
| Odds Of DistressLess than 20
|
Compass Therapeutics is trading at 1.38 as of the 22nd of November 2024; that is 0.73% up since the beginning of the trading day. The stock's open price was 1.37. Compass Therapeutics has about a 20 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Compass Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 23rd of October 2024 and ending today, the 22nd of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 5th of April 2021 | Category Healthcare | Classification Health Care |
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company was founded in 2014 and is headquartered in Boston, Massachusetts. Compass Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 137.59 M outstanding shares of which 1.79 M shares are currently shorted by private and institutional investors with about 3.71 trading days to cover. More on Compass Therapeutics
Moving against Compass Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Compass Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCompass Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Compass Therapeutics' financial leverage. It provides some insight into what part of Compass Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Compass Therapeutics (CMPX) is traded on NASDAQ Exchange in USA. It is located in 80 Guest Street, Boston, MA, United States, 02135 and employs 32 people. Compass Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 189.87 M. Compass Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 137.59 M outstanding shares of which 1.79 M shares are currently shorted by private and institutional investors with about 3.71 trading days to cover.
Compass Therapeutics currently holds about 132.02 M in cash with (40.62 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.31.
Check Compass Therapeutics Probability Of Bankruptcy
Ownership AllocationCompass Therapeutics holds a total of 137.59 Million outstanding shares. Over half of Compass Therapeutics' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Compass Ownership Details
Compass Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2024-06-30 | 2.3 M | |
| Cormorant Asset Management, Llc | 2024-06-30 | 2 M | |
| State Street Corp | 2024-06-30 | 1.9 M | |
| Baker Bros Advisors Lp | 2024-09-30 | 1.6 M | |
| Northern Trust Corp | 2024-09-30 | 844.4 K | |
| Monashee Investment Management Llc | 2024-09-30 | 500 K | |
| Millennium Management Llc | 2024-06-30 | 433.8 K | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 335.8 K | |
| Cm Management, Llc | 2024-09-30 | 310 K | |
| Orbimed Advisors, Llc | 2024-06-30 | 22.4 M | |
| Adage Capital Partners Gp Llc | 2024-06-30 | 11.1 M |
Compass Therapeutics Historical Income Statement
Compass Stock Against Markets
Compass Therapeutics Corporate Management
| Karin BA | VP Operations | Profile | |
| Susan Kalled | Chief Officer | Profile | |
| Jonathan JD | Head VP | Profile | |
| MD MBA | Chief Officer | Profile | |
| Neil CPA | Vice Finance | Profile | |
| Peter Moesta | Interim CMC | Profile | |
| Anna Gifford | Communications Manager | Profile |
Additional Tools for Compass Stock Analysis
When running Compass Therapeutics' price analysis, check to measure Compass Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compass Therapeutics is operating at the current time. Most of Compass Therapeutics' value examination focuses on studying past and present price action to predict the probability of Compass Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compass Therapeutics' price. Additionally, you may evaluate how the addition of Compass Therapeutics to your portfolios can decrease your overall portfolio volatility.